The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 29 of the 56 sources its claims cite were checked for support.
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Open accessAbstract
OPINION STATEMENT: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving with the advent of PSMA-targeted radioligand therapies (RLTs) and bispecific T-cell engagers (BiTEs). These novel approaches provide new hope for patients who have progressed on standard therapies. However, their full clinical potential will be realized only by addressing key challenges, including tumor heterogeneity, resistance mechanisms, immune-related toxicities, and the immunosuppressive tumor microenvironment. Additionally, the optimal sequencing of these therapies at different stages of disease remains an open question. While most of these interventions are currently introduced in late-stage, heavily pretreated patients, ongoing clinical trials are exploring their role in earlier disease settings, where they may be more effective in altering the natural history of disease. PSMA-based RLTs, such as 177Lu-PSMA- 617, have demonstrated promising efficacy, particularly in patients with high PSMA expression. However, the presence of PSMA-negative or heterogeneous tumors necessitates the development of additional biomarkers and combination strategies. The ongoing PSMAddition trial may establish RLTs as an earlier-line treatment in hormone-sensitive metastatic prostate cancer, potentially shifting the standard of care. Moreover, mitigating toxicities through radioprotective agents may aid in expanding their clinical utility. BiTE therapies offer a different but complementary mechanism of action, leveraging T-cell engagement to drive tumor cell destruction. While cytokine release syndrome (CRS) and immunogenicity remain significant hurdles, modifications such as low-affinity CD3 binding and optimized dosing regimens are showing promise. The potential synergy of BiTEs with immune checkpoint inhibitors and tumor microenvironment-modulating agents should be further explored to enhance therapeutic efficacy. Given these advancements, the future of mCRPC treatment likely lies in a personalized, multimodal approach that integrates PSMA-based RLTs, BiTEs, and complementary therapies at earlier disease stages. Strategic biomarker-driven patient selection and combination regimens will be essential in optimizing outcomes while minimizing resistance and toxicity.
Overview
CoChat Summary
## TL;DR
This review summarizes emerging PSMA-based therapies and bispecific T-cell engagers for advanced prostate cancer, emphasizing how radioligand therapy and BiTEs are reshaping treatment of mCRPC. It concludes that these approaches are promising but still limited by heterogeneity, resistance, immunogenicity, and toxicity, and that earlier-line and combination strategies are under active study.
## Key findings
- In the phase III VISION trial, 177Lu-PSMA-617 improved overall survival (median 15.3 vs 11.3 months; HR 0.62, P < 0.001) and radiographic PFS (median 8.7 vs 3.4 months; HR 0.40, P < 0.001) versus standard care.
- In PSMAfore, 177Lu-PSMA-617 improved rPFS in taxane-naïve mCRPC after ARPI progression (11.6 vs 5.59 months; HR 0.49), with lower grade 3–5 adverse events than control and OS not yet mature.
- In the phase I acapatamab study, 133 patients had a 30.4% PSA50 response; CRS occurred in 97.4% during dose exploration and 98.2% during dose expansion, with grade ≥3 CRS in 23.4% and 16.1%, respectively; TE-ADAs were detected in 55% and affected exposure in 36%.
- In the phase 1a ENGAGER-PSMA-01 study of JANX0007, 16 heavily pre-treated mCRPC patients had 100% PSA50, 63% PSA90, and 31% PSA99 responses; CRS events were mainly cycle 1 and grades 1–2.
- For xaluritamig (AMG 509), a phase 1 study enrolled 97 heavily pretreated mCRPC patients and found 49% PSA50 and 30% PSA90 responses; CRS occurred in 72%, mostly during cycle 1, and 3% discontinued because of CRS.
## Methods
- Narrative review of PSMA-based therapies and BiTE therapies in advanced prostate cancer, with emphasis on mCRPC and some earlier-stage settings.
- Synthesizes data from phase 1, phase 2, phase 3, and retrospective studies, including trials such as VISION, PSMAfore, PSMAddition, ECLIPSE, SPLASH, and multiple BiTE/ADC studies.
- The article mainly uses descriptive comparison of trial outcomes (e.g., OS, rPFS, PSA50/PSA90, CRS, TE-ADAs, response rates, safety signals) rather than a new primary analysis.
## Limitations
- The paper itself states that tumor heterogeneity, PSMA-negative or heterogeneous tumors, primary and acquired resistance, immunogenicity, CRS, and the immunosuppressive tumor microenvironment limit efficacy and wider adoption.
- It notes that optimal sequencing, best dosing strategies, and how to mitigate toxicities remain unresolved. It also states that some trial designs may be limited by bias favoring experimental arms, non-representative control arms, stringent inclusion criteria, and the requirement for PSMA-positivity, which may reduce generalizability.
- Evident from the text: this is a review article, so it does not present a single unified patient cohort or original controlled analysis; instead, it compiles results across heterogeneous studies and endpoints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 Valid · 0 Not valid · 25 Not checked · 6 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In prostate cancer, PSMA is the most frequently targeted TAA due to its abundant expression on malignant cells, but other targets are currently being explored as well [26].”
§ PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future > Bispecific T-Cell Engager (BiTE) Therapies
What the sources say
- Partly supportedcites [26] Lampe H, Tam L, Hansen AR. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future. Front Pharmacol. 2024;15:1399802. sourceExperimental — accuracy not yet measured
Section 2.2.2 calls PSMA the most commonly targeted TAA in prostate cancer BiTE therapies to date and says it is highly expressed in prostate cancer. The claim omits the BiTE-therapy limitation and presents abundant expression as the reason PSMA is targeted most often; the passage does not explicitly establish that causal link. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Due to the limitations in durable antitumor activity and significant immunogenicity, acapatamab development was discontinued.”
§ PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future > Bispecific T-Cell Engager (BiTE) Therapies
What the sources say
- Partly supportedcites [28] Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, et al. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024;30(8):1488–500. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that initial antitumor activity was not sustained and that antidrug antibodies reduced drug exposure in many patients. It says future development is challenging, but does not state that acapatamab development was discontinued or establish limited durability and immunogenicity as the reasons for such a decision. The discontinuations in Results > Patient disposition refer to patients stopping treatment, not to the development program. (LLM, conf=0.86)
plainstates a causen = 133- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the requirement for PSMA-positivity on imaging could limit generalizability of trial results to the broader mCRPC patient population”
§ PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future > PSMA-Based Therapies
What the sources say
- Partly supportedcites [15] Schnog JB, Duits AJ, Samson MJ. Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit. BJC Rep. 2024;2(1):45. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says PSMAfore enrolled patients with PSMA-avid disease on imaging, supporting the claim about imaging-based selection. It does not say that this requirement limits generalizability to the broader mCRPC population. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a retrospective review study of 53 patients with mCRPC treated with ADT, subsequent treatment with 225 Ac-PSMA- 617 showed that 91% of participants had at least 50% decline in PSA (PSA50), with 96% of patients having any decline in PSA”
§ PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future > PSMA-Based Therapies
What the sources say
- Supportedcites [21] Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J Nucl Med. 2022;63(10):1496–502. source
The Materials and Methods describe a retrospective review of patients with mCRPC receiving 225Ac-PSMA-617 after ADT. The Conclusion identifies a series of 53 patients, and the Results (Response to 225Ac-PSMA-617 Therapy) report that 48 (91%) had at least a 50% PSA decline and 51 (96%) had any PSA decline. (LLM, conf=0.95)
plainstates a causen = 53- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“JNJ- 081, an alternate BiTE targeting PSMA, was studied in a 2023 phase 1 study of 39 patients and showed a PSA50 response of 7.7%.”
§ PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future > Bispecific T-Cell Engager (BiTE) Therapies
What the sources say
- Partly supportedcites [29] Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023;21(3):366–75. sourceExperimental — accuracy not yet measured
The Abstract (Results) confirms that 39 patients received JNJ-081 in this phase 1 study. The Results (Efficacy; page unavailable) report confirmed PSA declines greater than 50% in two patients, not a 7.7% PSA50 response rate; two of 39 is approximately 5.1%. (LLM, conf=0.90)
plainn = 39- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 11 with their cited sources checked
Create a free account to see all 60 claims and to verify the 5 references still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 4
Citations
Cites
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · cited 1×
“Of note, cabazitaxel was not allowed in the SOC arm [11].”
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100 · cited 1×
“For example, novel RLTs such as Actinium-225 PSMA-617 are being tested to overcome resistance to Lutetium-based therapies [6, 7].”
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · cited 1×
“For example, novel RLTs such as Actinium-225 PSMA-617 are being tested to overcome resistance to Lutetium-based therapies [6, 7].”
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386 · cited 2×
“This is at least in part due to oste-oclast-mediated resorption of bone tumors and subsequent release of TGF-β, which then impairs T Helper 1 cells and prevents a robust immune mediated effect [5].”
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
Davis, M. I., Bennett, M. J., Thomas, L. M., & Bjorkman, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502101102 · Cited by 296 · cited 1×
“Its extracellular domain enables ligand binding, followed by receptor-mediated endocytosis, which facilitates the internalization of therapeutic agents into cancer cells [9].”
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242 · cited 2×
“This is characterized by low T-cell infiltration, an abundance of suppressive cells such as regulatory T-cells and myeloid-derived suppressor cells, low tumor mutational burden, and metabolic and hormonal factors that impair immune activity [4].”
Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210 · cited 1×
“The median OS was 15.5 months (95% CI 13.4–18.3) and median PFS was 7.9 months, (6.8–8.9 mo) with xerostomia reported as a common treatment related side-effect [22].”
InfluentialEmmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00135-9 · Cited by 195
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158 · cited 1×
“This heterogeneity can lead to variable response rates to PSMA-targeted therapies and leave a treatment gap in patients with non-PSMA expressing prostate cancer, furthering the need for alternate biomarker investigation [35].”
Research works printed but not linked: 3
- Mutevelic S, Patterson M. Curium announces ECLIPSE trial has met primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer. Curium Pharma Press Release. 2024. https://www.curiumpharma.com/2024/11/13/eclipse-tiral-psma-prostate-cancer/.
- Hurley, S. LAVA reports third quarter 2024 financial results and announces pipeline reprioritization and cash runway extension into 2027. LAVA therapeutics press release. Dec 10 2024. https://ir.lavatherapeutics.com/news-releases/news-release-details/lava-reports-third-quarter-2024-financial-results-and-announces.
- Campbell, D. Janux announces doses selected for phase 1b expansion trials supported by encouraging efficacy and safety profile observed in phase 1a dose escalation for JANX007 in mCRPC. Janux therapeutics press release. Dec 2 2024. https://investors.januxrx.com/investor-media/news/news-details/2024/Janux-Announces-Doses-Selected-for-Phase-1b-Expansion-Trials-Supported-by-Encouraging-Efficacy-and-Safety-Profile-Observed-in-Phase-1a-Dose-Escalation-for-JANX007-in-mCRPC/default.aspx.
Cited by
Al-Karmalawy, A. A., Eissa, M. E., Ashour, N. A., Yousef, T. A., Khatib, A. O. A., & Hawas, S. S. (2025) · RSC Advances · doi:10.1039/d5ra05472a · Cited by 48
Radioligand Therapy in Cancer Management: A Global Perspective
Ninatti, G., Lee, S. T., & Scott, A. M. (2025) · Cancers · doi:10.3390/cancers17213412 · Cited by 36
Zhou, Z., Zhao, K., Xiao, X., Yang, W., Miao, Y., Wu, T., Kong, X., Tao, Y., Wang, W., & Dong, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105208 · Cited by 6
T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755512 · Cited by 2
“Strategic biomarker-driven patient selection, coupled with rational combination regimens, is essential for maximizing therapeutic ef fi cacy while minimizing resistance and treatment-related toxicity (104).”
Liu, F., Ge, C., Qiao, B., Aihemaiti, Z., Zhao, L., Zhang, W., Zebibula, A., & Rexiati, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1655082 · Cited by 4
Metadata
- Authors
- Ayzman, A., Pachynski, R. K., & Reimers, M. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Reimers, Melissa A.
- Venue
- Current Treatment Options in Oncology
- Published
- 2025-04-23
- Volume
- 26
- Issue
- 5
- Pages
- 375-384
- ISSN
- 1527-2729 (ISSN-L)
- 1534-6277
- PMC
- PMC12055665
- OpenAlex
- W4409704743
- Cited by
- 18
- References
- 42
- Citations by year
- 2026: 14 · 2025: 4
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Current Treatment Options in Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic castration-resistant prostate cancer, PSMA radioligand therapy, 177Lu-PSMA-617, bispecific T-cell engagers, tumor heterogeneity, treatment resistance, immune-related toxicity, cytokine release syndrome, tumor microenvironment, immunosuppression, radiation protection, biomarkers, hormone-sensitive prostate cancer, immune checkpoint inhibitors, combination therapy
- MeSH terms
- Antigens, Surface, Combined Modality Therapy, Humans, Male, Neoplasm Staging, Prostatic Neoplasms, Biomarkers, Tumor, Treatment Outcome, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Molecular Targeted Therapy, Tumor Microenvironment, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future. https://app.cochat.ai/papers/10.1007/s11864-025-01317-5
- The paper
- Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025). PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-025-01317-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.